Interferon Lambda 3

Interferon Lambda 3 (IFNL3), previously known as Interleukin 28B (IL28B), is a type of interferon that plays a crucial role in the immune response to viral infections, particularly in the liver. It is part of the interferon lambda family, which are key players in the body's antiviral defense mechanisms. IFNL3 has been extensively studied for its impact on the treatment and natural history of Hepatitis C (HCV) infection.

Function

Interferon Lambda 3 is produced by hepatocytes (liver cells) and certain dendritic cells in response to viral infection. It binds to a unique receptor complex, distinct from the receptors used by type I interferons, which is expressed on fewer cell types. This specificity leads to a more targeted antiviral response, primarily in the liver, with potentially fewer side effects compared to the broader activity of type I interferons. IFNL3 induces the expression of interferon-stimulated genes (ISGs) that inhibit viral replication.

Genetic Variants and Hepatitis C

The gene encoding IFNL3 has several single-nucleotide polymorphisms (SNPs) that have been linked to the outcome of Hepatitis C virus infection. Certain genetic variants of IFNL3 are strongly associated with spontaneous clearance of the virus without the need for treatment, as well as with the response to interferon-based therapy. These discoveries have led to the development of genetic tests that can predict an individual's response to Hepatitis C treatments, allowing for more personalized therapy approaches.

Clinical Significance

Research has shown that individuals with certain IFNL3 genotypes are more likely to achieve a sustained virologic response (SVR) when treated with interferon-based therapies for Hepatitis C. This has significant implications for the management of HCV, as patients with favorable IFNL3 genotypes may be more likely to benefit from certain treatments. Additionally, the study of IFNL3 has contributed to the understanding of why some individuals are able to clear HCV infection spontaneously, while others develop chronic infection.

Future Directions

The discovery of IFNL3 and its role in viral infections opens up new avenues for research and therapy. Drugs that can modulate the activity of IFNL3 or its pathway could potentially offer new treatments for Hepatitis C and other liver diseases. Moreover, understanding the mechanisms by which IFNL3 influences the immune response to HCV may lead to novel therapeutic strategies that can enhance viral clearance and prevent chronic infection.

See Also

• Interferon
• Hepatitis C
• Viral hepatitis
• Antiviral drug

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian